靶向炎症性皮肤病中白细胞介素23/Th17轴的生物制剂——从基础到临床  

Biological agents targeting interleukin-23/Th17 axis in inflammatory skin diseases:from basic research to clinical application

作　　者：尤睿璇 曾茁桐 邱湘宁[1] 肖嵘[1] You Ruixuan;Zeng Zhuotong;Qiu Xiangning;Xiao Rong(Department of Dermatology and Venereology,The Second Xiangya Hospital of Central South University,Changsha 410011,China)

机构地区：[1]中南大学湘雅二医院皮肤性病科,长沙410011

出　　处：《中华皮肤科杂志》2023年第11期1065-1069,共5页Chinese Journal of Dermatology

基　　金：国家自然科学基金(82073449)。

摘　　要：白细胞介素17(IL-17)已被证明与各种炎症性皮肤病的发病密切相关,其主要来源是IL-23辅助分化的Th17细胞,因此IL-23/Th17轴是治疗炎症性皮肤病的新兴靶点。最新的临床试验表明,IL-17、IL-23和IL-12/23拮抗剂在治疗银屑病、特应性皮炎、化脓性汗腺炎、毛发红糠疹和SAPHO综合征患者中显示出良好的疗效与安全性。本文综述IL-23/Th17轴在炎症性皮肤病发生中的分子信号通路和病理生理基础的研究进展以及相应生物制剂的临床应用。Interleukin-17(IL-17)has been proved to be closely associated with the pathogenesis of various inflammatory skin diseases.Its main source is Th17 cells,whose differentiation is evoked by interleukin-23(IL-23).Therefore,the IL-23/Th17 axis is an emerging target for the treatment of inflammatory skin diseases.IL-17 antagonists,IL-23 antagonists and IL-12/23 antagonists have shown satisfactory efficacy and safety in the treatment of psoriasis,atopic dermatitis,hidradenitis suppurativa,pityriasis rubra pilaris and SAPHO syndrome in latest clinical trials.Accordingly,this review mainly summarizes progress in molecular signaling pathways in and pathophysiological basis of the IL-23/Th17 axis in the occurrence of inflammatory skin diseases,as well as clinical application of different biological agents targeting this axis.

关 键 词：生物制剂 白细胞介素17 白细胞介素23 银屑病 皮炎 特应性 炎症性皮肤病 

分 类 号：R751[医药卫生—皮肤病学与性病学]